Lady Davis Institute Distinguished Lecture Series: David Scadden, M.D.
Cancer through a stem cell lens
David Scadden, MD
Gerald and Darlene Jordan Professor of Medicine at Harvard University
Co-Director, Harvard Stem Cell Institute
Professor; Department of Stem Cell and Regenerative Biology, Harvard University
Director, Center for Regenerative Medicine
Massachusetts General Hospital
Tuesday, November 19th, 2019
LDI BLOOMFIELD LECTURE HALL, F-4 (Ground Floor)
David Scadden is the Gerald and Darlene Jordan Professor of Medicine at Harvard University. He is Professor and Chair emeritus of the Harvard University Department of Stem Cell and Regenerative Biology. He co-founded and co-directs the Harvard Stem Cell Institute with Prof. Douglas Melton. He is a hematologist/oncologist at the Massachusetts General Hospital where he founded and directs the Center for Regenerative Medicine and previously led the Hematologic Malignancies Program of the MGH Cancer Center. He is a member or fellow of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Association for the Advancement of Science, the American College of Physicians, and a former member of the Board of External Experts for the National Heart, Lung and Blood Institute and the National Cancer Institute’s Board of Scientific Counselors. He is an Affiliate Member of the Broad Institute of Harvard and MIT and a Visiting Scholar of Pembroke College, University of Cambridge, England. He co-founded the public companies, Fate Therapeutics and Magenta Therapeutics and is a Director of Agios Pharmaceuticals and Editas Medicines. His work emphasizes using multidisciplinary approaches to define novel therapies for blood diseases. He received the E. Donnall Thomas Award from the American Society of Hematology for his pioneering work on the bone marrow microenvironment. He is credited with having first experimentally defined a mammalian stem cell niche and its role in malignancy. His work on blood stem cells has led to new approaches to bone marrow transplantation and to differentiation therapy now in clinical trial for leukemia.
Host: Dr. François Mercier (514) 340-8222 x27840 / e-mail: email@example.com